FCODF yields 0.38% · JNJ yields 2.14%● Live data
📍 FCODF pulled ahead of the other in Year 1
Combined, FCODF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FCODF + JNJ for your $10,000?
Compagnie de l'Odet operates in the transport and logistics, and communication sectors in France, Africa, the Americas, the Asia-Pacific, and other European countries. The company operates through Transportation and Logistics, Oil Logistics, Communication, and Electricity Storage and Systems segments. The Transportation and Logistics segment provides maritime, and air transport and logistics services. The Oil Logistics segment distributes oil products. The Communication segment engages in the sale of recorded music on physical media or digital form; exploitation of copyrights and services to artists; editing and distribution of pay and free television channels; production, sale, and distribution of motion pictures and TV series; design and publishing of downloadable video games for mobiles and consoles; and provision of ticketing services, and communication and advertising agency consultancy. The Electricity Storage and Systems segment produces and sells electric batteries for electric vehicles, terminals and specialized systems, and plastic films, as well as telecommunications activities. It also manages a portfolio of financial investments. The company was formerly known as Financière de l'Odet SA and changed its name to Compagnie de l'Odet in May 2021. The company was incorporated in 1929 and is headquartered in Paris, France. Compagnie de l'Odet is a subsidiary of Bolloré SE.
Full FCODF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.